The settlement removes litigation overhang and secures LYBALVI exclusivity until at least late 2039. Monitor FTC/DOJ review and any potential earlier entry triggers. No immediate revenue impact, but the clarity on generic entry timing supports long-term revenue visibility for LYBALVI.
Drug in focus
ALKS drug pipeline →LYBALVI
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (FDA approved May 28, 2021). A pediatric label expansion, if supported by the ENLIGHTEN-Youth trial, would be a supplemental approval, typically 6-12 months after data submission.
- Next catalyst
- None dated
What to watchWatch for topline results from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results unreported as of Nov 4). Positive data could support a label expansion into adolescents, opening a new patient segment. Separately, LYBALVI's expanded payer access (~80% of covered lives) should drive prescription volume growth into 2027, though gross-to-net adjustments are expected to rise to ~45%.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $46.98entry
- T+1 · 4d ago +0.11%α +0.47% · $47.03
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Alkermes settled a patent infringement lawsuit with Teva over LYBALVI (olanzapine/samidorphan). Teva will receive a license to launch a generic version no earlier than November 12, 2039 (or May 12, 2040 if pediatric exclusivity is obtained), resolving the ANDA litigation. The settlement removes near-term generic risk but defers the revenue impact by over a decade.
Key Facts
- Alkermes and Teva entered a Confidential Settlement and License Agreement on November 6, 2026, resolving patent litigation over LYBALVI.
- Teva will receive a non-exclusive, royalty-free license to market its generic version of LYBALVI beginning November 12, 2039, or May 12, 2040 if pediatric exclusivity is granted.
- The lawsuit was filed by Alkermes against Teva in the U.S. District Court for the District of New Jersey regarding Teva's ANDA No. 220379.
- The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026.
- The settlement is subject to review by the U.S. FTC and DOJ.
Financial Impact
No financial terms disclosed; the license is royalty-free. The settlement pushes generic entry to late 2039/2040, preserving LYBALVI exclusivity for approximately 13 years from the filing date.
Risk Factors
- FTC or DOJ review could challenge or modify the settlement terms.
- Earlier generic entry is possible under certain circumstances not detailed in the filing.
- LYBALVI revenue concentration risk remains if the product is a significant portion of Alkermes' total revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-456888 |
| Document: 0001193125-26-456888-index-headers.html | 0001193125-26-456888 |
| Document: 0001193125-26-456888-index.html | 0001193125-26-456888 |
| Document: 0001193125-26-456888.txt | 0001193125-26-456888 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers